How Do the Two Available Single-Inhaler Triple Therapies for COPD Compare?

An observational study suggests some small differences in outcomes.

Guidelines (e.g., Global Initiative for Chronic Obstructive Lung Disease 2025 GOLD Report) suggest that patients with chronic obstructive pulmonary disease (COPD), a history of frequent or severe exacerbations, and blood eosinophils ≥300 cells/mL be considered for “triple” therapy — a long-acting β-agonist, a long-acting muscarinic, and a corticosteroid. In the U.S., two single-inhaler triple therapies are available: Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol), a metered-dose inhaler that is used twice daily, and Trelegy Ellipta (fluticasone, umeclidinium, and vilanterol), a dry-powder inhaler that is used once daily.

Given an absence of head-to-head randomized trials comparing these two options, researchers conducted thi…

Reviewing Authors

Steven T. Kariya, MD

Disclosures

Leadership positionBoard member of Metropolitan District of Columbia Thoracic Society

Steven T. Kariya, MD

Disclosures

Leadership positionBoard member of Metropolitan District of Columbia Thoracic Society

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

How Do the Two Available Single-Inhaler Triple Therapies for COPD Compare?

Topics

Reviewing Authors